Robert Z Orlowski

In this enlightening discussion, Professor Meletios-Athanasios C Dimopoulos from Greece and Dr. Robert Z Orlowski from the University of Texas delve into the latest clinical advancements in multiple myeloma treatment. They explore groundbreaking therapies like tri-specific T cell engagers and belantamab's re-approval in the UK. The duo also emphasizes the significance of minimal residual disease monitoring and compares the efficacy of CAR-T therapies, shedding light on their impact on patient care and future research directions.

Dr. Robert Orlowski, an expert in multiple myeloma from MD Anderson Cancer Center, joins the discussion on groundbreaking ASH 2024 research. They explore the AQUILA study revealing early daratumumab intervention benefits, and a meta-analysis promoting quadruplet therapy as the new standard. The benefits of CAR-T therapy for lenalidomide-refractory patients are also highlighted. Furthermore, the use of IVIG alongside BCMA-targeted therapies shows promise in reducing infections and improving survival rates. Tune in for vital insights on the future of myeloma treatment!

In this engaging discussion, Prof. Philippe Moreau from France, Dr. Robert Z Orlowski from MD Anderson, Dr. Noopur Raje from Massachusetts General, and Dr. Paul G Richardson delve into the complexities of managing multiple myeloma. They tackle innovative treatment strategies, including the use of CD38 antibodies, novel therapies, and the importance of minimal residual disease as a prognostic marker. The conversation also covers challenges in treating elderly patients, the role of CAR T-cell therapies, and the potential of the new BELLA drug in improving outcomes.